|
Biological Activity:
an oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition.
References: online
SM Wilhelm et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer. 2011, 129(1), 245-55. [online]
Chemical Name: 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide
Regorafenib - BAY 73-4506 | Multikinase inhibitor | Axon Medchem | Axon 1678 | BAY73-9006 - BAY 734506 - BAY734506 |